In summary, the novel mechanism presented here opens new avenues to therapeutically target mutant KRas-dependent human cancers by suppressing GSK3α/β, leading to β-catenin- and/or c-Myc-dependent tumor abrogation. This evidence concerns the gene GSK3A and neoplasm.